Targeting tomoregulin for radioimmunotherapy of prostate cancer

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2846-2853

  Zhao, Xiao Yan ^a   Schneider, Doug ^a   Biroc, Sandra L ^a   Parry, Renate ^a   Alicke, Bruno ^a   Toy, Pamela ^a   Xuan, Jian Ai ^a   Sakamoto, Choitsu ^b   Wada, Ken ^b   Schulze, Michael ^c   Müller Tiemann, Beate ^c   Parry, Gordon ^a   Dinter, Harald ^a  

^a BAYER AG   (Germany)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY 2H8 Y 90; ANTINEOPLASTIC AGENT; INDIUM 111; MEMBRANE PROTEIN; RADIOACTIVE MATERIAL; RADIOISOTOPE; TOMOREGULIN MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BRAIN; CONTROLLED STUDY; CROSS REACTION; EPITHELIUM; GROWTH RATE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TUMOR CELL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; INDIUM RADIOISOTOPES; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; RNA, MESSENGER; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTERBIUM;

EID: 20144388954     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4019     Document Type: Article

References (20)

1. Raghavan D, Skinner E. Genitourinary cancer in the elderly. Semin Oncol 2004;31:249-63.
2. Small EJ. Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol 2004;22:2515-6.
3. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703-6.
4. Krishnan AV, Zhao XY, Swami S, et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 2002;5:1889-900.
5. Zhao XY, Ly LH, Peehl DM, Feldman D. Induction of androgen receptor by 1α,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999;140:1205-12.
6. Uchida T, Wada K, Akamatsu T, et al. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999;266:593-602.
7. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22:387-90.
8. Horie M, Mitsumoto Y, Kyushiki H, et al. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics 2000;67:146-52.
9. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci U S A 2001;98:265-70.
10. Liang G, Robertson KD, Talmadge C, Sumegi J, Jones PA. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res 2000;60:4907-12.
11. Glynne-Jones E, Harper ME, Seery LT, et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001;94:178-84.
12. Mohler JL, Morris TL, Ford OH III, Alvey RF, Sakamoto C. Gregory CW. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 2002;51:247-55.
13. Afar DE, Bhaskar V, Ibsen E, et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 2004;3:921-32.
14. Stove C, Vanrobaeys F, Devreese B, Van Beeumen J, Mareel M, Bracke M. Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. Oncogene 2004 Jul 8;23:5330-9.
15. Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, Schulte-Hermann R. Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 2002 Sep;35:1-5.
16. Gery S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002;21:4739-46.
17. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997 Nov 27;15:2705-16.
18. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537-40.
19. Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Can Res 1995;55:5857-63.
20. 90Y-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.